A16z investment, Baijian CEO in command! Cardiovascular drug developer Braveheart (BRVE.US) to sprint for Nasdaq IPO.

Clinical-stage biopharmaceutical company Braveheart Bio Inc., supported by A16z, submitted an IPO application to NASDAQ on Wednesday. This cardiovascular disease drug developer will seek to raise funds of an undisclosed amount by selling shares on the NASDAQ Global Market. The company's lead candidate drug is BHB-1893, currently in development for the treatment of hypertrophic cardiomyopathy. To date, the company has raised $185 million from investors including a16z's biotechnology fund and Patient Square Capital. Christopher Viehbacher, CEO of Biogen (BIIB.US), serves as Chairman of Braveheart. Braveheart reported a net loss of $14.3 million in the first three months of 2026, generating around $11 million in revenue. In comparison, the net loss in the same period last year was $99,000. Goldman Sachs Group, Inc., Jefferies Financial Group Inc., Daiwa Capital, Stifel, and Cantor are serving as joint underwriters for the offering. Braveheart will trade under the stock symbol "BRVE".